- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Volume 2012 (2012), Article ID 549875, 6 pages
miR-320 Regulates Glucose-Induced Gene Expression in Diabetes
1Department of Pathology, Western University, London, ON, N6A 5C1, Canada
2London Health Science Centre, 339 Windermere Road, London, ON, N6A 5A5, Canada
Received 18 April 2012; Accepted 22 June 2012
Academic Editors: C. Bizzarri, J. Mittag, and H. Tamemoto
Copyright © 2012 Biao Feng and Subrata Chakrabarti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
miRNAs play an important role in several biological processes. Here, we investigated miR-320 in glucose-induced augmented production of vasoactive factors and extracellular matrix (ECM) proteins. High glucose exposure decreased the expression of microRNA 320 (miR-320) but increased the expression of endothelin 1 (ET-1), vascular endothelial growth factor (VEGF), and fibronectin (FN) in human umbilical vein endothelial cells (HUVECs). Transfection of miR-320 mimics restored ET-1, VEGF and FN mRNA, and protein expression in HUVECs treated with high glucose. Furthermore, miR-320 mimic transfection reduced glucose-induced augmented production of ERK1/2. Data from this study indicates that miR-320 negatively regulates expression of ET-1, VEGF, and FN through ERK 1/2. Identification of such novel glucose-induced mechanism regulating gene expression may offer a new strategy for the treatment of diabetic complications.
microRNA- (miRNA-) mediated regulation of gene expression has emerged as a major mechanism in regulating basal and stress-induced alterations of gene expression in several diseases [1–5]. miRNAs are endogenous, single-stranded, nonprotein coding RNAs, approximately 19–24 nucleotides in length, that are major posttranscriptional regulator of RNA [6, 7]. Most miRNAs negatively regulate gene expression at the posttranscriptional level, by interacting with their target mRNA 3′ untranslated region (UTR) . Mature miRNA sequences are also highly conserved among species. Interestingly, based largely on bioinformatics analyses, one miRNA may regulate a large number of target genes, and a single gene may also be regulated by multiple miRNAs, targeting various sites of the gene . They have been implicated as players in multiple biologic processes such as differentiation, proliferation, apoptosis, and in providing feedback loops for various signal transduction pathways [7, 9].
Recent data from several laboratories have emerged with respect to miRNA alterations in diabetic complications [10–12]. We have shown that miRNA-mediated gene regulation in diabetes interacts with other epigenetic changes such as histone acetylation [10, 11]. We and others have demonstrated alterations of miR-133a in cardiomyocyte hypertrophy in diabetes [11, 13]. We have recently demonstrated that miR-200b regulates VEGF and control permeability and angiogenesis in diabetic retinopathy . We have also shown that increased fibronectin (FN) production in chronic diabetes is regulated by miR-146a .
In diabetes, glucose induced augmented expression of vasoactive factors and ECM proteins are important mechanisms causing tissue damage . Several investigators have demonstrated augmented expression of vasoactive factors such as endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and extracellular matrix (ECM) proteins such as FN in all organs, affected by chronic diabetic complications [10, 11, 14, 15]. Oxidant injury in hyperglycemia is known to activate multiple signalling pathways which in turn lead to increased expression of several such molecules . Such signalling pathways include activation of mitogen-associated protein kinases (MAPK) [17, 18]. We and others have shown that extracellular signal-regulated kinase ERK 1/2 activation can be regulated by protein kinase C (PKC) [17, 19]. In addition, diabetes-induced ET-1 upregulation can also cause MAPK activation . Hence, it appears that several interactive molecules and signalling pathways may contribute to alteration of the effector vasoactive factors and ECM proteins in diabetes. As miRNAs control expression of almost all biological molecules, it is possible that several of these factors are also posttranscriptionally controlled by specific miRNAs. Furthermore, as one gene may be regulated by multiple miRNA, it is potentially possible to modulate transcription of multiple genes using a single miRNA.
In this study, we focused on a specific miRNA, that is, miR-320, which demonstrated glucose-induced downregulation. miR-320 has been found to have widespread biological effects as it regulates multiple important molecules. Its potential targets include ET-1, ERK1, VEGF, and FN (http://www.microrna.org/). Its biologic actions include effects on carcinogenesis, development, and ischemia reperfusion injury . In a recent study, serum level of miR-320 was found to be reduced in the diabetic population . On the other hand, increased miR-320 has been demonstrated in the cardiac microvascular cells in the diabetic rats . As endothelial cells are primary targets in diabetic complications, we used a well-established Human Umbilical Vein Endothelial Cells (HUVECs) for these studies. We and others have demonstrated glucose-induced alterations of the multiple molecules in these cells [10, 11, 19].
2. Materials and Methods
2.1. Cell Culture and Treatments
All reagents were purchased from Sigma (Oakville, ON, Canada) unless specified. HUVECs were obtained from Bio-Whittaker (San Diego, CA, USA) and plated in complete endothelial growth medium supplemented with 5% fetal bovine serum, endothelial cell growth supplement (Bio-Whittaker), and 100 ug/mL penicillin/streptomycin. Cells were plated at a density of cells/mL. They were treated with glucose (25 mmol/L). After 24 h in serum-free, the cells were transfected with miRIDIAN micro RNA Mimic miR-320 (100 nM) (DHARMACON Inc., Chicago, IL, USA) using transfection reagent Lipofectamin, 2000 (Invitrogen, ON, Canada). Negative control miRNA, (100 nM) were used for control transfection.
2.2. Microarray Analysis for miRNA Expression
Total miRNAs were extracted from HUVECs using the mirVana miRNA isolation kit (Ambion, Inc., Austin, TX, USA), according to the manufacturer’s instruction. Briefly, the cells were collected and lysated in the Lysis/Binding solution. miRNAs additive (1 : 10) were added to the lysate and incubated for 10 minutes on ice. And equal volume acid-phenol : chloroform was added to the lysate. Following centrifugation and removal of the aqueous phase, the ethanol was added into the mixture. The mixture was passed through the filter cartridge and was eluted with elution solution.
miRNA expression profiling was performed following the protocol provided by the manufacturer (Life Technologies, ON, Canada). In brief, 1 ug of isolated total miRNAs was added with Megaplex RT primer, dNTPs, MultiScribe reverse transcriptase, RNase inhibitor, and buffer to perform megaplex reverse transcription. Following reverse transcription, the real-time PCR reactions mixture was prepared to mix the Megaplex RT product with TaqMan universal pCR master mix, No AmpErase UNG (2x). The real-time PCR reactions mixture was dispensed into each port of the TaqMan microRNA array card to run the array using the 384-well TaqMan low-density array default thermal cycling conditions in the 7900HT system (life Technologies, ON, Canada). The results were shown using relative quantification ().
2.3. miRNA Validation by Real-Time RT-PCR
miRNAs were isolated using mirVana RT-PCR miRNA isolation kit. RT was performed after isolating of miRNA (Ambion Inc., Austin, TX, USA). TaqMan real-time PCR was used to analyze the expression of miR-320 by using miR-320 assay (Ambion Inc., Austin, TX, USA) following manufacture’s instruction. The data were normalized to U6 snRNA to account for differences in reverse-transcription efficiencies and amount of template in the reaction mixtures.
2.4. Real-Time RT-PCR for mRNA
RNA was extracted with TRIzol reagent (Invitrogen Canada Inc., ON, Canada) as previously described (total RNA (2 μg), was used for cDNA synthesis with cDNA reverse-transcription kit (Applied Biosystems Inc., CA, USA). Real-time quantitative RT-PCR was performed using the LightCycler as described [10, 11] (Roche Diagnostics Canada, QC, Canada). The primer sequences have been listed in Table 1. For more details about β-actin, see Table 1. β-actin mRNA was used as an internal control.
2.5. Western Blotting
The cells were washed with PBS and lysed with ice-cold RIPA lysis buffer (Upstate, Temecula, CA, USA). Cell lysates were loaded to 10% SDS-PAGE gel and blotted with high-affinity rabbit polyclonal anti-ERK1/2 antibody (Cell Signaling Technology Inc., Danvers, MA, USA) followed by incubation with goat antirabbit secondary IgG antibody with horseradish peroxidase conjugate (Santa Cruz Biotechnology, Inc., CA, USA) using 1 : 5000 dilutions. Immunopositive bands were visualized with enhanced chemiluminescence advance Western blot detection system (Amersham Biosciences, Piscataway, NJ, USA). Blots were stripped and reprobed with β-actin (1 : 2000) as an internal control.
2.6. ELISA for ET-1 and FN Expression
Supernatants were collected from HUVECs cultured for FN, ET-1, and VEGF detection by ELISA. ELISA for FN was performed using a commercially available kit (Abcam, Cambridge, MA, USA) according to the manufacturer’s instructions. Similarly, ET-1 and VEGF were measured using specific ELISA kit (Biomedica Medizinprodukte GmbH & Co KG, Wien, Austria) following the manufacturer’s instructions.
2.7. Statistical Analysis
All experimental data are expressed as means ± SE and were analyzed by ANOVA or Student t-test as appropriate. A P value of 0.05 or less was considered significant.
3.1. miR-320 Is Downregulated in the Endothelial Cells (ECs) in Response to Elevated Glucose Levels
Hyperglycemia is a key initiating factor for endothelial damage in diabetes. To identify underlying mechanisms of tissue damage, we initially analyzed miRNAs in ECs exposed to 5 mM (simulating euglycemia, LG) and 25 mM (simulating hyperglycemia, HG) glucose, using an miRNA PCR-array. Twenty-five mM glucose exposure for 24 hrs caused significant downregulation of 20 miRNAs and upregulation of 24 miRNAs.
Using open-sourced softwares (http://www.targetscan.org/, http://www.microrna.org/, http://www.ebi.ac.uk/) for miRNA target predictions, miR-320 (identified to be significantly downregulated in the endothelial cells exposed to high glucose) was found to be associated with ET-1, VEGF, and FN. We verified the downregulation of miR-320 with qRT-PCR in the ECs (Figure 1(a)). No change in miR-320 level was observed when the cells were challenged with 25 mM L-glucose (osmotic control).
3.2. miR-320 Is Downregulated in the Kidneys of Diabetic Animals
We then wanted to see whether such changes are indeed of significance in a clinically relevant model of diabetic complication. To this extent, we examined renal cortical tissues from STZ diabetic rats, one month after onset of diabetes, as increased ECM proteins along with augmented ET-1 and VEGF production are known to occur in diabetic nephropathy. Diabetic animals showed hyperglycemia, glucosuria, and reduced body weight gain (data not shown). Analyses of miR-320 levels demonstrated a significantly reduced miR-320 level in the renal cortex of these animals (Figure 1(b)).
3.3. miR-320 Regulates Glucose-Induced Upregulation of Vasoactive Factors and ECM Protein in the Endothelial Cells
To establish a cause-effect relationship, we again used HUVECs as an in vitro model system. As previously mentioned, we and others have shown that endothelial cells exposed to high levels of glucose (simulating hyperglycemia) recapitulate molecular and functional features of diabetic vascular pathologies including upregulation of FN, ET-1, and VEGF [10, 11, 19].
In parallel to decreased miR-320 level upon exposure to HG, mRNA levels of ET-1 and VEGF (measured by qRT-PCR) were increased. Such increases were prevented by miR-320 mimic transfection (Figure 2). Transfection efficiencies, assessed by measuring miR-320, expression showed >10-fold increase in intracellular miR-320 expression compared to scrambled miRNA transfection. We did similar experiments with ECM matrix protein FN. Glucose-induced FN upregulation in the HUVECs was significantly prevented by miR-320 mimic transfection (Figure 2).
As microRNAs are posttranslational modifiers, we further examined protein levels of FN and ET-1 using ELISA. In keeping with RNA data miR-320 transfection prevented glucose induced upregulation of FN and ET-1. No effects were seen when cells were transfected with scrambled mimic (Figure 3).
3.4. miR-320 Regulates ERK1/2
As mentioned earlier, ERK1/2 activation plays a significant role in increased vasoactive factor and ECM protein production in diabetes through PKC activation or through ET-1. Furthermore, miR-320 targets ERK. Hence, we used Western blot using antibodies against total and Phospho-ERK. miR-320 mimic transfection significantly reduced ERK1/2 protein levels and glucose induced ERK1/2 phosphorylation (Figure 4).
In this study, we demonstrated that miR-320 is downregulated following glucose exposure to the endothelial cells and in the kidneys of diabetic rats. We have further showed that glucose induced upregulation of multiple vasoactive factors and extracellular matrix protein FN are regulated by miR-320. We also demonstrated that such regulations possibly work through MAPK modulation.
Following initial identification by a PCR-based microarray, we validated glucose induced downregulation of miR-320 in the endothelial cells. We also found that such downregulation is present in the kidneys of diabetic rats. We then demonstrated functional significance of these changes at the mRNA and protein levels using miR mimic transfection and normalization of glucose-induced upregulation of specific transcript. Our data indicated a role of ERK1/2 in this process. We used HUVECs to identify the in vitro biologic significance, which is a well-studied cell system in vascular biology, including the study of diabetic complications [10, 11, 19]. Although miRNA320 reduction has been demonstrated in the serum of diabetic individual and in the cardiac microvascular cells of diabetic rodents, this is the first study that demonstrated functional significance of such changes . This study also demonstrates a potential therapeutic implication of miR-320 in chronic diabetic complications as it is able to modulate multiple transcripts.
miRNAs highly conserved molecules across the species. They are produced as small, nonprotein coding RNAs and mostly negatively regulate gene expression at the posttranscriptional level by interacting with their target mRNA 3′ untranslated region (UTR) [1, 5]. Most target mRNA predictions for miRNAs stem from computational analysis examining sequence complementarity [6, 7].
As we start to understand functions of various miRNAs, with their widespread role in biological processes, several of them appear to play significant roles in chronic diabetic complications. We have previously demonstrated the role of miR-133a in diabetic cardiomyopathy . Other investigators have shown the role of miR-192 in diabetic nephropathy . We have also recently demonstrated downregulation of miR200b and 146a in several chronic diabetic complications [10, 11]. The mechanisms by which hyperglycemia causes cellular damage in the context of chronic diabetic complications are indeed complex and are not fully understood. However, it is now accepted that glucose-induced oxidative stress plays an important role . Such oxidative stress causes DNA damage and modifies transcription machinery through the activation of the redoxsensitive transcription factors . Increased oxidative stress causes altered expression of a number of genes including VEGF, ET-1, and FN . All such transcripts may, however, be post translationally regulated by miRNAs. Hence, miRNAs lend themselves to be therapeutic agents. However, the challenge for miRNA research is to define the function of specific miRNAs in various tissues and in the context of specific disease state.
In summary, we have identified a specific miRNA, that is miR-320 in the endothelial cells exposed to high glucose. We have also demonstrated that miR-320 is important in the regulation of several transcripts of interest in chronic diabetic complications. Understanding such novel pathways will help to better understand pathogenesis of chronic diabetic complications and pave the pathways toward the development of novel adjuvant treatment.
- A. Zampetaki and M. Mayr, “MicroRNAs in vascular and metabolic disease,” Circulation Research, vol. 110, no. 3, pp. 508–522, 2012.
- Y. Li, Y. H. Song, F. Li, T. Yang, Y. W. Lu, and Y. J. Geng, “MicroRNA-221 regulates high glucose-induced endothelial dysfunction,” Biochemical and Biophysical Research Communications, vol. 381, no. 1, pp. 81–83, 2009.
- E. E. Creemers, A. J. Tijsen, and Y. M. Pinto, “Circulating MicroRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?” Circulation Research, vol. 110, no. 3, pp. 483–495, 2012.
- B. S. Kasinath and D. Feliers, “The complex world of kidney MicroRNAs,” Kidney International, vol. 80, no. 4, pp. 334–337, 2011.
- D. Landi, F. Gemignani, and S. Landi, “Role of variations within microRNA-binding sites in cancer,” Mutagenesis, vol. 27, no. 2, pp. 205–210, 2012.
- J. Liu, M. A. Valencia-Sanchez, G. J. Hannon, and R. Parker, “MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies,” Nature Cell Biology, vol. 7, no. 7, pp. 719–723, 2005.
- L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004.
- Z. Yang and L. Wang, “Regulation of MicroRNA expression and function by nuclear receptor signaling,” Cell and Bioscience, vol. 1, no. 1, article 31, 2011.
- A. S. Flynt and E. C. Lai, “Biological principles of microRNA-mediated regulation: shared themes amid diversity,” Nature Reviews Genetics, vol. 9, no. 11, pp. 831–842, 2008.
- K. McArthur, B. Feng, Y. Wu, S. Chen, and S. Chakrabarti, “MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy,” Diabetes, vol. 60, no. 4, pp. 1314–1323, 2011.
- B. Feng, S. Chen, K. McArthur et al., “miR-146a-mediated extracellular matrix protein production in chronic diabetes complications,” Diabetes, vol. 60, no. 11, pp. 2975–2984, 2011.
- M. Kato, J. Zhang, M. Wang et al., “MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3432–3437, 2007.
- A. Carè, D. Catalucci, F. Felicetti et al., “MicroRNA-133 controls cardiac hypertrophy,” Nature Medicine, vol. 13, no. 5, pp. 613–618, 2007.
- C. G. Schalkwijk and C. D. A. Stehouwer, “Vascular complications in diabetes mellitus: the role of endothelial dysfunction,” Clinical Science, vol. 109, no. 2, pp. 143–159, 2005.
- S. Chen, M. D. Apostolova, M. G. Cherian, and S. Chakrabarti, “Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells,” Laboratory Investigation, vol. 80, no. 8, pp. 1311–1321, 2000.
- M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001.
- A. P. Lakshmanan, R. A. Thandavarayan, K. Watanabe et al., “Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice,” Molecular and Cellular Endocrinology, vol. 348, no. 1, pp. 104–111, 2012.
- A. P. Lakshmanan, M. Harima, V. Sukumaran et al., “Modulation of AT-1R/AMPK-MAPK cascade plays crucial role for the pathogenesis of diabetic cardiomyopathy in transgenic type 2 diabetic (Spontaneous Diabetic Torii) rats,” Biochemical Pharmacology, vol. 83, no. 5, pp. 653–660, 2012.
- X. Xin, Z. A. Khan, S. Chen, and S. Chakrabarti, “Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis,” Laboratory Investigation, vol. 84, no. 11, pp. 1451–1459, 2004.
- X. P. Ren, J. Wu, X. Wang et al., “MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20,” Circulation, vol. 119, no. 17, pp. 2357–2366, 2009.
- A. Zampetaki, S. Kiechl, I. Drozdov et al., “Plasma MicroRNA profiling reveals loss of endothelial miR-126 and other MicroRNAs in type 2 diabetes,” Circulation Research, vol. 107, no. 6, pp. 810–817, 2010.
- X. H. Wang, R. Z. Qian, W. Zhang, S. F. Chen, H. M. Jin, and R. M. Hu, “MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 2, pp. 181–188, 2009.
- B. Feng, S. Chen, B. George, Q. Feng, and S. Chakrabarti, “miR133a regulates cardiomyocyte hypertrophy in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 1, pp. 40–49, 2010.
- C. Wang, B. George, S. Chen, B. Feng, X. Li, and S. Chakrabarti, “Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats,” Diabetes/Metabolism Research and Reviews, vol. 28, no. 4, pp. 329–337, 2012.